L
ung cancer remains the most frequent cause of cancer death in both men and women in North America. It was estimated that there were 164,100 new lung cancer cases in the United States in the year 2000, with an estimated 156,900 deaths due to this highly lethal malignancy. This accounts for approximately 14% of all cancers diagnosed but 28% of all cancer deaths. 1 This suggests that the risk of developing a bronchogenic carcinoma is approximately 1 in 12 for male subjects and 1 in 18 for female subjects (birth to death, based on cases diagnosed during from 1994 to 1996). 1 Of the 419 new cases of cancer diagnosed at the Richard L. Roudebush VA Medical Center in 1998, lung cancer was the most common, comprising 131 cases, which reflects the overall aging of the US Department of Veterans Affairs population and apparent high rates of tobacco abuse. Of these, 112 cases were non-small cell lung carcinoma (NSCLC). Approximately 25% of these patients presented with stage I or II disease. Optimally, the definitive management of these cases of early stage lung carcinoma is considered to be surgical, with a 60 to 80% 5-year survival time. 2, 3 In contrast, the management of those patients with early stage bronchogenic carcinoma deemed medically inoperable is less clear. Involved-field radiotherapy is generally considered the treatment of choice for those patients who cannot undergo surgery, 4 but no randomized trials have examined the benefit of radiotherapy to patients compared with observation. With the advent of nationwide programs screening high-risk patients for lung carcinoma, it will be important to understand the natural history of the disease to develop a rational approach to the treatment of medically inoperable lung cancer. We review the results of the management of stage I and II lung cancers within the Richard L. Roudebush VA Medical Center between 1994 and 1999.
Results

Patient Population
All patients with a diagnosis of stage I and IIa NSCLC (T1-2N0 -1M0) as defined by the American Joint Committee on Cancer (1997) were retrieved from the institutional tumor registry at the Richard L. Roudebush VA Medical Center. All cases had been reviewed following diagnosis by the institutional multidisciplinary tumor conference where staging and disposition were discussed. Included in the analysis were those patients with squamous cell, adenocarcinoma, and non-small cell carcinoma not otherwise specified. The time period covered included from 1994 to 1999 and was stratified by those patients receiving no therapy, radiation therapy only, or surgery only. One hundred twenty-eight patients were identified for analysis. Of these, 49 patients (45 node negative and 4 T1 node positive) were found to have received no treatment, 36 patients (32 node negative and 4 T1 node positive) received radiation therapy only, and 43 patients (all node negative) were treated with primary surgery. Probability of survival from time of diagnosis was calculated by Kaplan-Meier method (Fig 1) , and a log-rank test was used to provide pairwise treatment comparisons.
Stage I and II Patients Not Receiving Treatment
All patients in this series were male. Average age was 70.8 years (range, 54 to 85 years). Of the 49 patients analyzed, 14 patients refused treatment and the remainder were not treated for a variety of medical reasons, most commonly COPD (18 patients). Mean size of the lung mass was 3.1 cm at time of diagnosis. Pulmonary function as measured by the FEV 1 ranged from 0.42 to 2.4 L (mean, 1.43 L). Of 43 patients analyzed, the median Ϯ SD survival time was 14.2 Ϯ 2.37 months. There was no significant difference in survival between stage I and stage IIa patients. The cause of death was cancer in 53% (26 cases) and other causes 30% (15 cases), with four patients having no reported cause of death. Four patients remained alive (Table 1) .
Stage I and II Patients Receiving Radiotherapy Only
Thirty-six patients received radiotherapy only for their stage I or IIa NSCLC. These patients had an average age of 70.4 years (range, 45 to 85 years). The reasons for referral for radiation therapy included postobstructive atelectasis (nine cases), hemoptysis (three cases), increasing tumor size (six cases), pain (three cases), pleural effusion (one case), and medical inoperability (eight cases). Reason for referral was not stated in seven cases. The mean size of the lung mass at diagnosis was 4.0 cm. Mean FEV 1 at time of referral was 1.7 L (11 cases; Table 1 ). Radiotherapy doses showed no consistency in total dose and fractionation. Of the 36 patients receiving radiotherapy, 20 different fractionation schemas were used, varying from 1,950 cGy in 200 cGy fractions to 7,050 cGy in 180 cGy fractions. Several patients received twice-daily fractionation. Twenty of 36 patients received doses Ͼ 60 Gy. Median survival time was 19.9 Ϯ 5.6 months (p ϭ 0.447, not significant compared to untreated patients). The cause of death was cancer in 43% (16 patients), other causes in 35% (13 patients), and 8 patients were alive at the time of analysis (Table 1) . Radiotherapy was stratified into curative intent (Ͼ 60 Gy, conventional daily, or twice-daily fractionation) vs palliative intent (large fraction size, limited doses). Those receiving curative radiotherapy had a 20.8 Ϯ 3.16-month median survival time (n ϭ 13 patients) compared with those receiving palliative radiotherapy (n ϭ 23 
Stage I and II Patients With Surgical Resection
Forty-three patients received curative resection, all with lobectomy. Mean age of these patients was 66 years (mean FEV 1 , 2.09 Ϯ 0.66 L). Average size of tumors resected was 3.04 cm. Median survival time was 46.2 Ϯ 3.15 months, which was highly significant compared with either untreated patients (p ϭ 3.2 ϫ 10 -6 ) or those receiving radiotherapy (p ϭ 0.0005).
Discussion
Surgery is the preferred form of treatment for early stage NSCLC, with many reviews showing a 60 to 80% 5-year survival rate. 2, 3 The data reported here confirm this optimistic outlook. In contrast, the outcome of the subset of patients reviewed here who did not undergo surgical management of their cancers was dismal. Of the 128 stage I and II patients seen at the Richard L. Roudebush VA Medical Center between 1994 and 1999, 85 patients (66%) were declared inoperable, most commonly for medical reasons. Due to the lack of prospective trials to assess the benefit of definitive radiotherapy to patients with early stage lung carcinoma, no firm treatment policies for these patients are in place. As seen in the patients managed with radiotherapy only, many different radiation regimens were used. The characteristics of the patients and their reason for referral for radiotherapy is predominantly that of palliative intent as the patient's disease progressed and they began to experience symptoms (eg, atelectasis, hemoptysis). Radiotherapy seems to have been reserved for symptomatic therapy rather than with curative intent. We attempted to stratify patients based on treatment intent, comparing those who received radiotherapy with curative intent with those who received palliative courses of treatment only. While the median survival time of those patients treated with curative intent was approximately 5 months longer than the patients undergoing palliative radiotherapy, statistical significance was not achieved, likely due to the small numbers involved. The cause of death in the patients receiving no therapy was lung cancer in 53% of patients. In this retrospective review, only the International Classification of Disease, Ninth Revision cause of death is available, listing lung cancer vs other causes of death, eg, cardiac, stroke, etc. Given that some of the patients had no cause of death reported in the registry, the estimates of cancer as cause of death may be conservative. It is clear that many patients with initial diagnoses with stage I or II lung cancer will die of their cancer despite the presence of many comorbidities.
Local radiotherapy to a limited volume of tissue is considered the standard therapy for patients with stage I or II NSCLC who do not receive surgery due to refusal or medical comorbidity; however, no randomized trials to compare the outcome of radiotherapy to observation only have been done. Thus, the natural history of untreated NSCLC is not clear. Vrdoljak et al 5 reviewed 130 patients with newly diagnosed lung cancer between from 1980 to 1987 and found that essentially all patients died within 36 months of diagnosis. Due to the rarity of untreated early stages, no T1N0 patients and only one T2N0 patient were included in the analysis. This study confirms the dismal outcome for untreated lung cancer.
Flehinger and Melamed 6 reviewed a multi- The present study does not answer the question of the benefit of local radiotherapy in the treatment of early stage, medically inoperable NSCLC. The lack of a consistent policy for the management of these patients has resulted in many of them being observed for significant periods of time with radiotherapy reserved for symptomatic or palliative therapy. Radiotherapy delivered to these patients also was found to be offered in a nonconsistent manner. Nonetheless, significant numbers of those patients not receiving therapy died of their cancer. The approach to management of these patients is not clear, but the trend to screening of patients for early stage NSCLC will result in the identification of increasing numbers of patient for whom therapy decisions other than surgery must be made. The malignant nature of lung cancer has made prospective clinical trials with a best supportive care arm for these early stage lung cancers not feasible. Thus, the benefit of conventional local radiotherapy for these patients and the natural history of early stage lung cancer become relevant.
